Bio-Techne (TECH) Total Non-Current Liabilities (2014 - 2026)
Bio-Techne's quarterly Total Non-Current Liabilities came in at $443.6 million in Q1 2026, down 27.34% year-on-year from $610.6 million in Q1 2025, and down 9.21% quarter-over-quarter from $488.6 million in Q4 2025.
Bio-Techne has reported Total Non-Current Liabilities for 13 years, with the latest figure at $443.6 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 27.34% year-over-year to $443.6 million; the trailing twelve-month figure through Mar 2026 stood at $443.6 million (down 27.34% YoY), and the FY2025 full-year result was $612.0 million, down 1.59% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $443.6 million, down from $488.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $749.8 million in Q4 2023, with the low at $443.6 million in Q1 2026.
- Average Total Non-Current Liabilities over 5 years is $606.2 million, with a median of $588.1 million recorded in 2022.
- Year-over-year, Total Non-Current Liabilities surged 41.67% in 2023 and fell 27.34% in 2026.
- Tracing TECH's Total Non-Current Liabilities over 5 years: stood at $529.3 million in 2022, then jumped by 41.67% to $749.8 million in 2023, then dropped by 22.57% to $580.6 million in 2024, then decreased by 15.84% to $488.6 million in 2025, then slipped by 9.21% to $443.6 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $443.6 million (Q1 2026), $488.6 million (Q4 2025), and $536.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Bio-Techne | 7.92 Bn | 7.71 Bn | 208.29 Mn | 443.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 443.63 Mn |
| Dec 31, 2025 | 488.63 Mn |
| Sep 30, 2025 | 536.52 Mn |
| Jun 30, 2025 | 611.98 Mn |
| Mar 31, 2025 | 610.58 Mn |
| Dec 31, 2024 | 580.60 Mn |
| Sep 30, 2024 | 577.58 Mn |
| Jun 30, 2024 | 621.86 Mn |
| Mar 31, 2024 | 695.24 Mn |
| Dec 31, 2023 | 749.83 Mn |
| Sep 30, 2023 | 748.22 Mn |
| Jun 30, 2023 | 661.26 Mn |
| Mar 31, 2023 | 699.04 Mn |
| Dec 31, 2022 | 529.30 Mn |
| Sep 30, 2022 | 588.07 Mn |
| Jun 30, 2022 | 581.56 Mn |
| Mar 31, 2022 | 581.77 Mn |
| Dec 31, 2021 | 590.57 Mn |
| Sep 30, 2021 | 605.63 Mn |
| Jun 30, 2021 | 673.42 Mn |
| Mar 31, 2021 | 529.60 Mn |
| Dec 31, 2020 | 511.22 Mn |
| Sep 30, 2020 | 583.83 Mn |
| Jun 30, 2020 | 619.45 Mn |
| Mar 31, 2020 | 706.05 Mn |
| Dec 31, 2019 | 672.38 Mn |
| Sep 30, 2019 | 745.67 Mn |
| Jun 30, 2019 | 693.60 Mn |
| Mar 31, 2019 | 706.86 Mn |
| Dec 31, 2018 | 730.41 Mn |
| Sep 30, 2018 | 753.06 Mn |
| Jun 30, 2018 | 504.80 Mn |
| Mar 31, 2018 | 550.38 Mn |
| Dec 31, 2017 | 504.30 Mn |
| Sep 30, 2017 | 526.40 Mn |
| Jun 30, 2017 | 540.19 Mn |
| Mar 31, 2017 | 621.11 Mn |
| Dec 31, 2016 | 600.85 Mn |
| Sep 30, 2016 | 618.46 Mn |
| Jun 30, 2016 | 211.80 Mn |
| Mar 31, 2016 | 265.80 Mn |
| Dec 31, 2015 | 273.89 Mn |
| Sep 30, 2015 | 287.23 Mn |
| Jun 30, 2015 | 213.22 Mn |
| Mar 31, 2015 | 249.24 Mn |
| Dec 31, 2014 | 298.28 Mn |
| Sep 30, 2014 | 224.14 Mn |
| Jun 30, 2014 | 67.23 Mn |